Platelet GPIba is a mediator and potential interventional target for NASH and subsequent liver cancer

Mohsen Malehmir; Dominik Pfister; Suchira Gallage; Marta Szydlowska; Donato Inverso; Elena Kotsiliti; Valentina Leone; Moritz Peiseler; BGJ Surewaard; Dominik Rath; Marco Prinz; Hellmut G. Augustin; Josep M. Llovet; Roser Pinyol; Frank Tacke; Roland Rad; Nabil Djouder; Paul Kubes; Percy A. Knolle; Kristian Unger; Lars Zender; Bernhard Nieswandt; Meinrad Gawaz; Achim Weber; Mathias Heikenwälder

doi:10.1055/s-0038-1677172

Back

Platelet GPIba is a mediator and potential interventional target for NASH and subsequent liver cancer

Zeitschrift für Gastroenterologie

Article 2019 English

Abstract

1 min read

Non-alcoholic fatty liver disease ranges from steatosis to non-alcoholic steatohepatitis (NASH), potentially progressing to cirrhosis and hepatocellular carcinoma (HCC).

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2021

From Liver Fat to Cancer: Perils of the Western Diet

Ju Youn Kim, Feng He, Michael Karin

Article2019

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)

Hannah K. Drescher, Sabine Weiskirchen, Ralf Weiskirchen

Article2015

Abstract PL03-03: ER stress and TNF signaling control the progression from simple steatosis to non-alcoholic steatohepatitis (NASH)

Michael Karin

Article2021

A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma

Marinela Krizanac, Paola Berenice Mass Sanchez, Ralf Weiskirchen, Anastasia Asimakopoulos

Article2019

Role of Inflammation in Control of Hepatic Lipid Metabolism—New Insights to the Pathogenesis of NASH

Michael Karin